<DOC>
	<DOCNO>NCT02594163</DOCNO>
	<brief_summary>This randomize , open-label , multicenter , Phase 2 clinical trial design evaluate efficacy safety brentuximab vedotin combination rituximab bendamustine treatment patient relapse refractory CD30-positive diffuse large B-cell lymphoma ( DLBCL ) failure second-line salvage therapy second-line treatment patient ineligible autologous stem cell transplant ( ASCT ) .</brief_summary>
	<brief_title>Study Rituximab Bendamustine With Without Brentuximab Vedotin CD30 Positive Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>Patients randomize 1:1 manner receive rituximab plus bendamustine without brentuximab vedotin . Patients respond combination treatment contain brentuximab vedotin experience excessive toxicity may receive additional single-agent brentuximab vedotin follow combination treatment , additional 10 cycle ( 16 total cycle treatment ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients confirm CD30positive DLBCL grade 3b follicular nonHodgkin lymphoma ( NHL ) . 2 . Patients must relapse refractory disease follow : 1. secondline great salvage systemic therapy , 2. frontline cytotoxic systemic therapy , patient ineligible stem cell transplant ( SCT ) . 3 . Age 18 year old . 4 . Fluorodeoxyglucose ( FDG ) avid disease positron emission tomography ( PET ) . 5 . An Eastern Cooperative Oncology Group ( ECOG ) performance status score 02 . 6 . Acceptable blood test result . 7 . Females childbearing potential must negative pregnancy test result within 7 day prior first dose study drug . 8 . Females childbearing potential male partner childbearing potential must agree use effective contraceptive method study 6 month follow last dose brentuximab vedotin 12 month follow last dose rituximab , whichever later . 9 . Patients must provide write informed consent . 1 . History another invasive malignancy remission least 1 year . ( Exceptions nonmelanoma skin cancer , curatively treat localized prostate cancer , ductal carcinoma , cervical carcinoma squamous intraepithelial lesion PAP smear ) . 2 . History progressive multifocal leukoencephalopathy ( PML ) . 3 . Cerebral/meningeal disease related underlying malignancy , unless definitively treat . 4 . Viral , bacterial , fungal infection within 2 week prior first dose treatment . 5 . Chemotherapy , radiotherapy , biologics , and/or antitumor treatment immunotherapy complete 4 week prior first dose study drug . 6 . Females pregnant breastfeeding . 7 . Known allergy study drug ingredient contain drug formulation study drug . 8 . Known positive hepatitis B . Known active hepatitis C infection antiviral therapy hepatitis C within last 6 month . 9 . Known positive human immunodeficiency virus ( HIV ) . 10 . Patients previous allogeneic stem cell transplant . 11 . Previous treatment brentuximab vedotin bendamustine . 12 . Intolerable toxicity prior rituximab therapy . 13 . Current therapy investigational agent . 14 . Lung disease unrelated underlying malignancy . 15 . History stroke transient ischemic attack , unstable angina , myocardial infarction , cardiac symptom within 6 month prior first dose treatment . 16 . Congestive heart failure . 17 . Significant peripheral sensory motor neuropathy start study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>